Ajay K. Gopal
M.D., Emory University, Medicine, 1993.
B.S., Duke University, Zoology, 1989.
American Association for Cancer Research
American Society for Clinical Oncology
American Society of Hematology
2003-2007, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research Division
2003-2007, Assistant Professor, University of Washington, School of Medicine, Medicine, Oncology
1997-2000, Fellow in Medical Oncology, University of Washington, School of Medicine, Medicine, Oncology
1993-1996, Resident in Internal Medicine, Duke University, Duke University Medical Center, Medicine
Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(9):1582-1587.. 2016.
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting.. Clinical trials (London, England). 13(5):545-54.. 2016.
Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 23(4):254-259.. 2016.
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.. Cancer immunology research.. 2016.
Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2015.
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.. Leukemia & lymphoma. 56(1):92-6.. 2015.
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(2):281-7.. 2015.
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.. British journal of haematology. 171(5):788-97.. 2015.
New targeted therapies for indolent B-cell malignancies in older patients.. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 35:e365-74.. 2015.
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(9):1363-8.. 2014.
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine.. 2014.
A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies.. Cancer research. 74(4):1179-89.. 2014.
Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2014(1):151-7.. 2014.